LONDON (Dow Jones)--The U.K.'s healthcare costs watchdog Wednesday said GlaxoSmithKline PLC’s (GSK.LN) Revolade isn’t recommended for use on the state-funded National Health Service to treat patients having a rare blood condition.
LONDON (Dow Jones)--The U.K.'s healthcare costs watchdog Wednesday said GlaxoSmithKline PLC’s (GSK.LN) Revolade isn’t recommended for use on the state-funded National Health Service to treat patients having a rare blood condition.
